Conversion therapy for unresectable hepatocellular carcinoma: Advances and challenges

被引:0
作者
He, Yan-Fei [1 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 6, Dept Hlth Management Ctr, 6 Fucheng Rd, Beijing 100048, Peoples R China
关键词
Unresectable hepatocellular carcinoma; Conversion therapy; Challenges; Advances; Advanced hepatocellular carcinoma; Targeted therapy; Immunotherapy; PORTAL-VEIN LIGATION; RADIOFREQUENCY ABLATION; HEPATIC RESECTION; SORAFENIB; CHEMOTHERAPY; BEVACIZUMAB; COMBINATION; EFFICACY; PLUS;
D O I
10.4251/wjgo.v16.i10.4289
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recently, the World Journal of Gastrointestinal Oncology published an article entitled "Pathologically successful conversion hepatectomy for advanced giant hepatocellular carcinoma after multidisciplinary therapy: A case report and review of the literature", in which the authors shared their successful experience with complete surgical resection after multidisciplinary conversion therapy. The study by Chu et al demonstrates the great challenges that the advanced hepatocellular carcinoma (HCC) poses to surgical oncology, reveals the complexity of conversion therapy for unresectable HCC, emphasizes the important role of a multidisciplinary management model in conversion therapy, and enriches our understanding of the dynamics of personalized treatment for different patients. At present, conversion therapy is a hot research topic in the treatment of unresectable HCC, which has brought new hope to many patients with moderately advanced HCC. However, there are still many urgent problems to be solved in conversion therapy. Here, we would like to further discuss the advances and challenges of conversion therapy for unresectable HCC with the authors and the general readers.
引用
收藏
页码:4289 / 4297
页数:10
相关论文
共 50 条
  • [21] Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study
    Wu, Xu-Kun
    Yang, Lan-Fang
    Chen, Yu-Feng
    Chen, Zhong-Wu
    Lu, Hao
    Shen, Xue-Yi
    Chi, Min-Hui
    Wang, Liang
    Zhang, Hui
    Chen, Jia-Fei
    Huang, Jing-Yao
    Zeng, Yong-Yi
    Yan, Mao-Lin
    Zhang, Zhi-Bo
    ECLINICALMEDICINE, 2024, 67
  • [22] Benefit of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score-Matched Study
    Han, Ruyu
    Gan, Leijuan
    Sun, Liyu
    Lang, Mengran
    Tian, Xindi
    Zhu, Kangwei
    Chen, Lu
    Li, Guangtao
    Song, Tianqiang
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1835 - 1844
  • [23] Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma
    Ahmed, Zunirah
    Lee, Sunyoung S.
    Victor III, David W.
    Kodali, Sudha
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 1911 - 1922
  • [24] Advances in pharmacotherapeutics for hepatocellular carcinoma
    Cerrito, Lucia
    Santopaolo, Francesco
    Monti, Flavia
    Pompili, Maurizio
    Gasbarrini, Antonio
    Ponziani, Francesca Romana
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (10) : 1343 - 1354
  • [25] The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma
    Bai, Jinfeng
    Huang, Ming
    Song, Bohan
    Luo, Wei
    Ding, Rong
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [26] Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges
    Deng, Gan-Lu
    Zeng, Shan
    Shen, Hong
    WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (05) : 787 - 798
  • [27] Chemotherapy and target therapy for hepatocellular carcinoma:New advances and challenges
    Gan-Lu Deng
    Shan Zeng
    Hong Shen
    World Journal of Hepatology, 2015, 7 (05) : 787 - 798
  • [28] Real-world status, efficacy and prognosis analysis of first-line treatment for unresectable hepatocellular carcinoma in patients treated at multiple centres
    Liu, Jing
    Du, Qianyu
    Shao, Yu
    Xu, Han
    Liu, Xiuli
    Zhang, Wenting
    Wang, Mingxi
    Zhou, Zhengguang
    Kan, Qingsheng
    Yang, Yan
    ANNALS OF MEDICINE, 2024, 56 (01)
  • [29] Molecular Targeted Therapy in Hepatocellular Carcinoma: Present Achievements and Future Challenges
    Giacomin, Anna
    Sergio, Adriana
    Vanin, Veronica
    Gazzola, Alessia
    Cazzagon, Nora
    Farinati, Fabio
    DIGESTIVE DISEASES, 2012, 30 (03) : 284 - 288
  • [30] Lenvatinib as a therapy for unresectable hepatocellular carcinoma
    Spallanzani, Andrea
    Orsi, Giulia
    Andrikou, Kalliopi
    Gelsomino, Fabio
    Rimini, Margherita
    Riggi, Laura
    Cascinu, Stefano
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (11) : 1069 - 1076